Investors

Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations
Corporate Presentation
Annual Report and Proxy Statement
Date Title and Summary
Toggle Summary Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
- New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis   - Arena sponsored symposium: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us? SAN DIEGO , Oct. 9, 2020 /PRNewswire/ --  Arena Pharmaceuticals,
Toggle Summary Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome
- Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D)   - Topline data expected Q1 2021   - Significant unmet need for non-opioid, peripherally acting pain management in